Brandt J T, Miller L, Hermiller J, Unverferth D V, Leier C V
Clin Pharmacol Ther. 1984 Aug;36(2):260-4. doi: 10.1038/clpt.1984.172.
Amrinone is a cardiotonic agent associated with reversible thrombocytopenia in 20% to 50% of patients. The mechanism of thrombocytopenia is not known and it is not clear whether this effect represents a high-frequency idiosyncratic reaction or an overt manifestation of a toxic effect on platelet survival. We prospectively evaluated the effect of oral amrinone on platelet function and survival in seven subjects who participated in a clinical trial of chronic oral amrinone therapy. There was no consistent effect on either platelet function or platelet survival. Data suggest that amrinone does not have a uniform effect on platelet survival and that the development of thrombocytopenia may represent an idiosyncratic reaction.
氨力农是一种强心剂，20%至50%的患者使用后会出现可逆性血小板减少。血小板减少的机制尚不清楚，也不清楚这种效应是高频特异性反应还是对血小板存活毒性作用的明显表现。我们前瞻性地评估了口服氨力农对7名参与慢性口服氨力农治疗临床试验受试者血小板功能和存活的影响。对血小板功能和血小板存活均无一致影响。数据表明，氨力农对血小板存活没有统一作用，血小板减少的发生可能代表一种特异性反应。
